A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

NCT01659047 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: GS-1101

Sponsor

Gilead Sciences